Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

5.970 +0.220 (+3.83%)
Streaming Delayed Price Updated: 1:12 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,105
Open 5.790
Bid (Size) 5.960 (7)
Ask (Size) 5.980 (7)
Prev. Close 5.750
Today's Range 5.620 - 5.987
52wk Range 3.050 - 9.010
Shares Outstanding 43,471,030
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
FDA assigns PDUFA target action date of April 29, 2025 
From Abeona Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+7.96%
+7.96%
1 Month
-8.85%
-8.85%
3 Month
+13.93%
+13.93%
6 Month
+39.16%
+39.16%
1 Year
+43.17%
+43.17%

More News

Read More
Abeona Therapeutics® Announces Participation in November Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
From Abeona Therapeutics Inc.
Via GlobeNewswire
ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Abeona Therapeutics Inc.
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.